AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
Oct 3, 2024
OCALA, Fla., Oct. 03, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the...
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
Sep 30, 2024
OCALA, Fla., Sept. 30, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered...
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
Sep 27, 2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA, Fla., Sept. 27, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, Chief...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Sep 19, 2024
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no severe adverse events or dose-limiting toxicities OCALA, Fla., Sept. 19,...
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
Sep 11, 2024
Company is planning a follow-up clinical trial with a focused subject population of moderate-to-severe Post-COVID-related fatigueOCALA, Fla., Sept. 11, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced that an analysis of the complete clinical...
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Aug 20, 2024
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other drugs OCALA, Fla., Aug. 20, 2024 -- AIM ImmunoTech Inc. (NYSE...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 16, 2024
- Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications - Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 -- AIM ImmunoTech...
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
Aug 13, 2024
OCALA, Fla., Aug. 13, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q2 2024 operational and financial results on Friday, August 16, 2024 at...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Jul 29, 2024
OCALA, Fla., July 29, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an...
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
Jul 24, 2024
OCALA, Fla., July 24, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the publication of new pre-clinical data concerning the company's drug Ampligen as part of a combinational therapy in the treatment of melanoma, showing...